ArticleNature2021
CRL4
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 171 citations in OpenAlex.
- Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition.Nature immunology · 2026Article
- Cyclin D-CDK4/6 couple proliferation to membrane and mitochondrial protein supply through a DeSI1 phospho-switch.bioRxiv : the preprint server for biology · 2026Article
- Article
- Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening.Neuro-oncology · 2026Article
- Integrated Interactomics Reveals Novel Protein Associations: The FOXA1-PBX1 Complex as a Case Study.bioRxiv : the preprint server for biology · 2026Article
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- Article
- Ubiquitin-dependent degradation of p27Kip1 and p21Waf1/Cip1 by AMBRA1 ensures G1 and S phase progression and limits replication stress.Nucleic acids research · 2026Article
- Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells.FEBS open bio · 2026Article
- CRL4EMBO reports · 2026Article
- A novel synthetic melanin as a potential anticancer agent that induces apoptosis and cyclin D downregulation through distinct pathways.The Journal of biological chemistry · 2026Article
- Article
- Cuttlefish ink nanoparticle hydrogels ameliorate osteoarthritis via concurrent inhibition of macrophage pyroptosis and chondrocyte senescence.Journal of nanobiotechnology · 2026Article
- Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.Journal of hematology & oncology · 2026Review
- A proteome-wide dependency map of protein interaction motifs.Nature structural & molecular biology · 2026Article
- Pre-dauer starvation rapidly and reversibly reduces niche proliferative signaling to the Caenorhabditis elegans germ line.Development (Cambridge, England) · 2026Article
- A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.bioRxiv : the preprint server for biology · 2026Article
- Host E3 ligase RNF2 restricts African swine fever virus replication through targeting viral pA104R for its K5 site ubiquitination degradation.Cellular and molecular life sciences : CMLS · 2026Article
- CRL4International journal of biological sciences · 2026Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 3 countries.
Daniele SimoneschiDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-0448-4295
Gergely RonaDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-3222-7261
Nan ZhouDepartment of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9524-4275
Yeon-Tae JeongDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Shaowen JiangDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Giacomo MillettiDepartment of Pediatric Hemato-Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID http://orcid.org/0000-0003-2391-342X
Arnaldo A ArbiniLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.
Alfie O'SullivanDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Andrew A WangDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-8018-3828
Sorasicha NithikasemDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Sarah KeeganDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Yik SiuDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Valentina CianfanelliDepartment of Pediatric Hemato-Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID http://orcid.org/0000-0002-3857-9463
Emiliano MaianiCell Stress and Survival Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-1432-5394
Francesca NazioDepartment of Pediatric Hemato-Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Francesco CecconiDepartment of Pediatric Hemato-Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID http://orcid.org/0000-0002-5614-4359
Francesco BoccalatteLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1732-2033
David FenyöDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Drew R JonesDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA.
Luca BusinoDepartment of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. businol@upenn.edu.ORCID http://orcid.org/0000-0001-6758-9276
Michele PaganoDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA. michele.pagano@nyulangone.org.ORCID http://orcid.org/0000-0003-3210-2442
NYU Langone’s Laura and Isaac Perlmutter Cancer CenterBambino Gesù Children's Hospital · ITHoward Hughes Medical Institute · USInstitute for Systems Biology · USNew York University · USUniversity of Pennsylvania · USUniversity of Rome Tor Vergata · ITDanish Cancer Society · DK
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MF-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in CancerR01CA076584 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2021
$4.5MRole of KLHL6 inactivation in mature B-cell malignanciesR01CA207513 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Luca Busino · 2016 to 2026
$4.2MRegulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7MSandy Recovery Ventana Medical Systems Discovery XTS10OD018338 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHIRIBOGA, LUIS A · 2014 to 2014
$123kNCI NIH HHS P30 CA016087NCI NIH HHS R01 CA076584NCI NIH HHS R01 CA207513NIGMS NIH HHS R35 GM136250NIH HHS S10 OD018338Wellcome Trust
Abstract
D-type cyclins are central regulators of the cell division cycle and are among the most frequently deregulated therapeutic targets in human cancer
Indexed as
Cell DivisionAdaptor Proteins, Signal TransducingAnimalsCRISPR-Cas SystemsCyclin D1Cyclin D2Cyclin D3Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleGene Knockout TechniquesGenes, Tumor SuppressorHCT116 CellsHEK293 CellsHumansAdaptor Proteins, Signal TransducingAMBRA1 protein, humanAmbra1 protein, mouseCDK2 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin D1Cyclin D2Cyclin D3Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Ubiquitin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.